Our monthly Best Buys Now are designed to highlight our team’s three favourite, most timely Buys from our growing list of small-cap recommendations, to help Fools build out their stock portfolios.

Why we like it: “Tristel (LSE: TSTL), is an innovative healthcare firm based in Cambridge. Its unique disinfectant products are high-margin, quick to deploy, and cost effective. The recent regulatory approval for its DUO ultrasound product in the US has seen it enter the world’s largest ultrasound market – a significant opportunity long in the making. Encouragingly, it has already onboarded a growing number of hospital customers in the US.“The company has also received regulatory approval in Canada for a high-level disinfectant for ultrasound probes, bolstering its North American growth prospects. We hope that Tristel can build on its recent progress and eventually take a position as global market leader. The opportunity for investors in the firm is that Tristel’s top-line growth accelerates and its profitability increases as royalties from the product rollout in North America come on stream.”

Why we like it now: Tristel’s partnered with a US partner, Parker Laboratories, to manufacture and sell its Tristel ULT high level disinfection product to US hospitals. Tristel will receive a royalty on sales of 24%, which will produce lower revenues than selling direct, but with no direct costs meaning sales largely translate into operating profit. So far, commercial progress has been limited, with royalty income in the US of just £108k in the latest fiscal year partly due to ‘complex purchasing pathways’. However, the opportunity could be huge, given Tristel estimates an addressable market of $150m. Tristel says it has engaged with roughly 200 health systems with adoption ‘steadily building’ as Parker leverages its nationwide salesforce and distribution network. With Tristel also receiving FDA clearance earlier this year for a high-level disinfectant for ophthalmic instruments – Tristel OPH. The total market opportunity for Tristel OPH is around $32m per year. Tristel’s confident North America will make a ‘meaningful contribution to Group revenues over the coming years’. While investors await news of further progress in North America, the offers a trailing yield of 3.9% supported by strong cash generation.

The post Just released: our top 3 small-cap stocks to consider buying in December [PREMIUM PICKS] appeared first on The Motley Fool UK.

The possibility of a company being acquired isn’t — by itself — enough of a reason to buy a stock. But when a firm with strong long-term prospects becomes an acquisition possibility, I think the situation gets interesting.

Wizz

A lot of investors are actually betting against Wizz Air (LSE:WIZZ) shares. As of this month, at least five firms have disclosed short positions in the FTSE 250 company.

It’s easy to see why and I’ve no interest in buying the stock myself. But the possibility of a takeover is a big risk for investors actively betting against the share price.

Strategically, Wizz is shifting away from its attempt to offer low-cost long-haul flights to focus on the European market. And there are pros and cons to this strategy.

The big advantage is that the low-cost model actually works in Europe. Shorter distances make it possible to fit in more journeys with quick turnarounds.

The downside, however, is that there’s a lot more competition from the likes of easyJet and Ryanair. And a battle over prices can make profits hard to find for everyone.

That’s why I don’t like the firm’s long-term prospects and wouldn’t consider buying it. But Ryanair CEO Michael O’Leary expects Wizz to be acquired as part of a wider industry consolidation, and that could cause the stock to jump.

Tristel

Tristel (LSE:TSTL) is a very different stock – for one thing, the business is actually doing well at the moment. But I think it could still be a potential takeover target.

The company has US approval for its opthalmic wipes, to go with its ultrasound products. These make disinfecting surgical equipment faster and more effective.

While Tristel has a US distribution strategy, being acquired by a firm like, say, Johnson & Johnson would provide an easy route to market. And the stock does look cheap.

The main risk with the company is that its product is expensive. This means convincing US hospitals to buy its products – even if they’re better – won’t be straightforward.

Despite this, there’s a lot to like about the stock — disregarding the possibility of a takeover. A market value of £171m arguably doesn’t reflect the firm’s growth potential.

I sold my Tristel shares earlier this year when the price reached £4.20. But the stock is down 15% since then, and a 4% dividend yield means I’m taking another look.

Takeover targets 

Takeover news can cause a company’s shares to jump, but buying on this basis alone is a risky business. That’s why I’m staying away from Wizz — I don’t like the firm’s long-term prospects.

With Tristel, on the other hand, the situation is different. I like the look of the stock even if nobody comes to acquire it, so I think it’s worth considering as a potential buy.

The post These UK shares look like potential takeover targets, but should investors consider buying? appeared first on The Motley Fool UK.

Bioventix

What it does: Bioventix specialises in the supply of high-affinity monoclonal antibodies for applications in clinical diagnostics

By Paul Summers. There’s not an abundance of quality AIM-listed companies. One exception is arguably Bioventix (LSE: BVXP). The Farnham-based developer and commercial supplier of monoclonal antibodies consistently posts some of the highest operating margins in the entire UK stock market! 

All that said, investor confidence has been knocked after the company disclosed it had overstated revenues. Even though the miscalculation appears to be due to an error on the part of one of its customers, this has pushed the shares down significantly in value as a result of the company now failing to hit analyst expectations.

However, I reckon now is a great time to consider loading up. Bioventix remains a leader in its niche market. The current valuation is also significantly below the firm’s five-year average. While never guaranteed, the dividend yield currently stands at 5.8% and the balance sheet looks very healthy indeed. 

Paul Summers has no position in Bioventix.

dotDigital

What it does: A digital marketing enterprise helping businesse monetise their audiences and improve customer experience.

By Zaven Boyrazian. When it comes to digital marketing, dotDigital (LSE:DOTD) isn’t short on competition. Yet, as economic conditions have improved, the firm has continuously maintained double-digit revenue and profit growth that seems to have gone ignored by investors.

The small-cap enterprise now generates an average of £1,916 per month from each of its customers, almost double the amount compared to five years ago. And a big part of the rising spending trends is courtesy of management’s investments into its technology, including an AI prediction engine to maximise customer conversion through personalisation.

It’s a powerful tool that few of its competitors provide. And with new marketing channels like WhatsApp being added into the mix, dotDigital is slowly becoming a one-stop-shop for everything that is marketing.

Larger rivals like Hubspot remain a serious threat. However, with larger customers like Mountain Warehouse and British Airways joining the client list, this AIM-listed enterprise seems to be taking the right steps.

Zaven Boyrazian owns shares in dotDigital.

Serabi Gold

What it does: Serabi Gold owns a series of mining projects in Brazil, including the Palito and Coringa complexes.

By Royston Wild. Precious metal stocks like Serabi Gold (LSE:SRB) continue to go from strength to strength. This yellow metal miner is up a stunning 39% in the year to date, propelled by gold prices rising through the $3,000 per ounce marker for the first time.

With this key psychological and technical level taken out, metal values — and with them the prices of Serabi and its peers — could strengthen further.

The African miner’s low valuation certainly leaves room for further gains. Today it trades on a forward price-to-earnings (P/E) ratio of just 3.4 times.

I don’t just believe Serabi Gold is a great stock to consider buying for the current bull run, however. Through a blend of organic growth and acquisitions, the business has plans to turbocharge earnings by lifting production to 200,000 ounces a year over the next few years.

That’s up from the 60,000 ounces planned for 2026. Remember, though, that mining is risky business, and any setbacks at the exploration, production or mine development phases could prove disastrous for profits projections, and with it the share price.

Royston Wild does not own shares in Serabi Gold.

Tristel

What it does: Tristel makes and distributes chlorine dioxide wipes that are used for disinfecting hospital environments.

By Stephen Wright. Shares in Tristel (LSE:TSTL) have fallen almost 30% since the start of the year. I think that’s a lot for a company that still has a lot of potential. 

Tristel is in the process of expanding to start selling its (patented) chlorine dioxide wipes across the Atlantic. But getting into the US has proved challenging.

With a premium product, there’s always a danger of customers being unwilling to move away from established practices. And that’s the risk with the stock.

I think, however, the potential rewards are worth it. Tristel has been following up its ultrasound disinfectant system with a product for ophthalmic devices and this looks promising to me.

If the company can make a breakthrough on this front, I think there could be huge growth ahead. If not, there’s a dividend with a 4.6% yield to fall back on.

Stephen Wright owns shares in Tristel.

YouGov

What it does: YouGov is a market research and data analytics company.

By Alan Oscroft. In a first-half update on 31 March, YouGov (LSE: YOU) said it only “expects modest revenue growth for the rest of the financial year as trading conditions remain challenging reflecting the current macro-economic backdrop.“

The company is still searching for a new permanent CEO after Steve Hatch left by mutual agreement in February. And when interim CEO Stephan Shakespeare talks about a “resilient” performance, and he mentions “considerable change” and “execution challenges,” then we can tell things have been a bit tough.

But the company still says it should meet market expectations for the full year. And it expects operating profit to be balanced more equally between the two halves.

There are clearly risks here, and the share price could remain depressed for some time yet. But analysts expect positive earnings per share (EPS) this year, and then an 80% boost by 2027 that would take the price-to-earnings (P/E) ratio down to only about eight.

Alan Oscroft has no position in YouGov.

The post 5 AIM stocks to consider buying for the long term appeared first on The Motley Fool UK.

I see dividends as part of a bigger picture, rather than the sole focus of my investing. But, it hasn’t escaped my attention that my passive income is set for a boost.

Bunzl

Shares in FTSE 100 distribution firm Bunzl (LSE:BNZL) have a dividend yield of around 2.5%. That doesn’t sound like much, but I’ve got an eye on the long term.

Between now and 2027, Bunzl is set to invest £700m a year into growing via acquisitions. If it can’t do this, the firm is to use the cash for dividends and share buybacks. 

At today’s prices, that’s 7% of the firm’s market value. So I’m expecting at least that in terms of annual growth for the next few years – and I think it could well be much more.

Growing through acquisitions can be a risky business and making a mistake can set a company back years. Rentokil, for example, is still working through an acquisition from 2022.

In general though, buying businesses is riskier when they’re either large in size or involve the acquirer taking on significant debt. But I think Bunzl should be able to avoid this.

The FTSE 100 firm operates in an industry where competition is mostly fragmented. This should give it the chance to make relatively small acquisitions using its cash rather than debt.

Bunzl consistently achieves returns on invested capital of around 15%, which is a strong result. And I think the fragmented nature of the market means there’s a good chance this continues.

Tristel

I’ve also been adding to my investment in Tristel (LSE:TSTL). With a market cap of £153m, this one is at the other end of the scale to Bunzl, but I think it also has some impressive prospects.

The company makes chlorine dioxide wipes and foams for medical settings (equipment and surfaces). These are quicker and more effective than other decontamination methods.

Tristel is currently looking at US expansion. The firm has approval for its ultrasound wipes and is expecting to achieve the same for its ophthalmic product this year. 

That could be a huge opportunity. But the biggest risk for investors might not be the inherent uncertainty in getting the product signed off by regulators.

Tristel’s products are very good, but they’re also expensive and it’s looking to break into a market that has some well-entrenched practices. This won’t be straightforward, by any means.

Right now, however, the stock has a dividend yield of 4.5%. And the company has committed to growing this by 5% each year in the near term – regardless of what happens with the business. 

I take that as a sign that – unlike Bunzl – Tristel doesn’t need to use its cash to finance its growth prospects. That makes it very attractive from my perspective. 

Investing well

When it comes to investing, the thing to do is to focus on the underlying business first and foremost. Get that bit right and the dividends will follow.

Bunzl and Tristel are very different companies. But I’m optimistic about strong returns from both and I think their dividends will grow.

The post I’ve been boosting my dividend income with these UK shares appeared first on The Motley Fool UK.

I think this has been the case recently. There are a few shares that I see having become much more attractive since the start of the year – and I think investors should add them to their watchlists.

Judges Scientific

Judges Scientific (LSE:JDG) is a great example of the kind of stock I have in mind. It’s down 20% since the start of the year and it’s reached a level where I’ve actually started buying it for my portfolio.

The scientific equipment conglomerate has a market cap of £475m and generates around £16m in free cash. That’s around a 3.1% return, but I’m not interested in this one for the instant returns. 

The company looks attractive because it has a lot of scope for future growth. Primarily, I expect this to be driven by acquiring other businesses – which is something it has done very successfully in the past.

This can be risky – the danger of overpaying for an acquisition is real. But the lower the share price goes, the more I think investors have a margin of safety against this possibility.

Tristel

Another growth stock I think looks attractive at the moment is Tristel (LSE:TSTL). This is also stock I’ve been buying recently and it’s one investors should consider it too.

The stock is down almost 25% since the start of the year, but it could be on the verge of something important. The medical disinfectant company is in the process of expanding into the US market. 

This won’t necessarily be straightforward. Tristel’s products command a premium price and this means there’s a risk that hospitals might be reluctant to move away from existing solutions. 

The firm, however, has had some success with its wipes for ultrasound and it’s expecting approval for its ophthalmology solution this year. Over time, I think this could generate some significant growth.

Five Below

The S&P 500 might be in correction territory, but the US stock catching my eye at the moment is Five Below (NASDAQ:FIVE). It’s a discount retailer that I think has some exciting prospects. 

The company is hoping to reach 3,500 outlets, which is roughly double its current number. If it can do this, I expect a big boost to profits, but there are some potential challenges ahead. 

One of these is inflation. This is particularly relevant in the US at the moment and could mean consumer spending taking a hit, causing Five Below’s growth to come in slower than expected.

I think, however, that this is reflected in the share price. The stock trades at a price-to-earnings (P/E) ratio of 14, which isn’t what someone might expect to see from a company with big growth opportunities.

Off the beaten track

The stocks I’ve mentioned here aren’t ones that typically get a lot of attention. But I’m a firm believer in the idea that the best opportunities are often found in places where other investors aren’t looking. 

Until recently, Judges Scientific, Tristel, and Five Below had all been fairly expensive. With share prices falling, however, I think investors should add them to their watchlists.

The post 3 growth stocks for investors to add to their watchlists appeared first on The Motley Fool UK.

Tristel (LSE:TSTL) however, might be such a stock. It’s at a 52-week low, but the business is growing well and the company just increased its dividend by 8% – with more to come.

What is Tristel?

Tristel’s a stock that investors probably aren’t paying much attention to. But I think they could be missing out if they don’t at least take a closer look.

The company makes disinfectant products for medical equipment. And what sets it apart is its use of chlorine dioxide – rather than chlorine – in its products.

Source: Tristel Investor Presentation February 2025

Chlorine dioxide (CIO₂) has a few advantages over chlorine (CI₂). Microorganisms can’t build resistance to CIO₂, it’s more efficient than CI₂, and it doesn’t produce harmful by-products.

In short, Tristel’s products are both effective and require a lot of technical knowledge. And I think this could be a powerful combination going forward.

Outlook

Tristel’s been successful in the UK disinfection market. But the big opportunity is it’s trying to make progress with is the US, which could be huge for a business currently valued at £165m. This however, isn’t straightforward.

The company’s solutions are expensive and convincing hospitals to change from trusted suppliers offering cheaper products might be difficult. Despite this, Tristel’s made progress. Its disinfectant for ultrasound probes has been given regulatory approval and the firm has issued a filing for its ophthalmic devices treatment.

It’s worth noting that, while the US is a huge potential market, it’s not the only growth avenue. The company has also identified Spain, India, and Austria as potential opportunities for 2025.

Dividends

With several international expansion possibilities in progress, it’s natural to think Tristel isn’t likely to be returning cash to shareholders any time soon. But that would be a big mistake. The company currently distributes just under 14p per share in dividends – a yield of 4% at today’s prices. And it’s committed to increasing this by 5% a year going forward. 

Given the uncertainty around its international expansion, that might seem somewhat cavalier. If its plans go as hoped, Tristel will have to invest cash to support its growth. 

The company however, has no debt and the cash on its balance sheet‘s growing. And its latest 8% increase in its interim dividend is in line with the growth from the underlying business.

Risks and rewards

Over the last five years, Tristel’s share price has been all over the place as pandemic-driven demand gave way to unusually high inventory levels. But that volatility should be in the past.

With the stock at a 52-week low, I think investors should consider it. Expansion into the US brings a lot of uncertainty, but the share price offers good value for the risks involved.

If things go well, a £10,000 investment in Tristel today might be generating significant passive income 10 years from now. And the stock could be worth a lot more as well.

The post At a 52-week low, is this under-the-radar UK stock now an unmissable opportunity to consider? appeared first on The Motley Fool UK.

Shares in companies that have outstanding growth prospects rarely trade at heavily discounted prices. But I think they are still worth considering for patient long-term investors.

3i

Over the last 10 years, 3i (LSE:III) has grown its earnings per share at an average of 18% per year. And I think that’s the result of a durable competitive advantage that should continue going forward.

Unlike other private equity firms, 3i concentrates on investing its own capital. And this gives it a unique ability to wait for the right time to deploy cash in attractive opportunities.

The company’s portfolio is heavily exposed to a European discount retailer called Action. While the investment has been a great success, the concentration is a risk for investors to keep in mind.

Over time, I expect 3i to diversify its portfolio as opportunities present themselves. And it offers shareholders exposure to the kind of private companies they might not normally have access to.

Wise

I think Wise (LSE:WISE) might be the most impressive UK business I’ve ever seen. It facilitates overseas money transfers in a way that is cheaper, faster, and more reliable than its rivals.

One thing to note is that the company is currently earning a decent profit on the cash held in its accounts. If interest rates fall, there’s a risk this could fall quite significantly. 

That arguably makes the stock look cheaper than it really is. But even with the business of facilitating transfers in exchange for fees, I think there’s good scope for solid returns over time. 

Between April and September, the number of customers on Wise’s platform grew by 25%. I’m anticipating more to come going forward, with sales and profits from the core business to follow.

Tristel

Tristel (LSE:TSTL) makes disinfectant wipes and foams for medical purposes. Its chlorine dioxide products are over twice as effective as regular chlorine and don’t produce harmful by-products. 

Patent protection has historically limited the firm’s risk. But some patents have already lapsed and others expire in the next few years, removing a barrier to entry for potential rivals.

Management thinks, however, that the complicated nature of the products means copying them isn’t straightforward. And there’s a key growth opportunity that is potentially just getting started.

Tristel has begun selling its products in the US via a distributor. This opens up a huge market that I think could potentially generate substantial growth over the next 10 years. 

Long-term growth

None of the stocks I’ve mentioned here are obviously cheap at today’s prices. But I think each of them has the capacity to grow beyond their current market valuations. 

That’s the way it works with growth stocks. They might look expensive today, but if I’m right about their growth prospects, today’s prices might look like bargains 10 years from now.

The post 3 UK growth stocks to consider buying today and holding for a decade appeared first on The Motley Fool UK.

Our monthly Best Buys Now are designed to highlight our team’s three favourite, most timely Buys from our growing list of small-cap recommendations, to help Fools build out their stock portfolios.

Why we like it: “Tristel (LSE: TSTL), is an innovative healthcare firm based in Cambridge. Its unique disinfectant products are high-margin, quick to deploy, and cost effective. The recent regulatory approval for its DUO ultrasound product in the US has seen it enter the world’s largest ultrasound market – a significant opportunity long in the making. Encouragingly, it has already onboarded a growing number of hospital customers in the US.“The company has also received regulatory approval in Canada for a high-level disinfectant for ultrasound probes, bolstering its North American growth prospects. We hope that Tristel can build on its recent progress and eventually take a position as global market leader. The opportunity for investors in the firm is that Tristel’s top-line growth accelerates and its profitability increases as royalties from the product rollout in North America come on stream.”

Why we like it now: In its latest financial year, Tristel has seen sales and earnings climb by 16% and 32%, respectively, while remaining highly cash generative. The company ended the year with cash and equivalents of £11.8m and it has no debt. The company is set to receive royalty income from the sale of its Tristel ULT and Tristel DUO products in the US – which should potentially be a major source of future sales and profit growth. Earlier in the year, it said its partner in the US, Parker Laboratories, was doubling its salesforce which should help kickstart growth. Parker reckons “momentum” is building despite encountering “more purchasing bureaucracy than originally anticipated.” The company appears to be growing into its valuation, and while the recent change in CEO might introduce risk, the firm expects to see further growth in the new financial year while the longer-run opportunity still looks significant.

The post Just released: our top 3 small-cap stocks to consider buying in October [PREMIUM PICKS] appeared first on The Motley Fool UK.

Earnings have been increasing at pace. But the icing on the cake is the foothold the business has in the North American market.

If momentum builds in the US over the coming months and years, it’s possible the stock could perform well from where it is now.

Strong potential for growth ahead

The business is already well-established, profitable and expanding like mad. Just how I like it, with jam today and the potential for cases of the stuff in the future!

It’s Tristel (LSE: TSTL), the global infection prevention company that makes and supplies products using its proprietary chlorine dioxide (ClO₂) chemistry.

The firm’s products go to hospitals, and around 87% of sales come from its Tristel brand for the decontamination of medical devices. Another top seller is its Cache brand for the sporicidal disinfection of environmental surfaces, which delivers about 8% of total sales.

There’s been wide acceptance of the company’s offering and that shows in the multi-year trading figures. Double-digit percentage annual increases in earnings have become normal. City analysts predict more ahead for the current trading year to June 2025 with an uplift of about 20%.

Today’s (21 October) full-year report for the year to June 2024 is robust and “ahead of expectations“. The directors also included an upbeat outlook statement. That’s not surprising because the business is making big strides abroad.

Overseas sales and modest profits

For example, today’s figures show the firm earned more revenue from overseas than it did in the UK. Just under 48% of revenue came from the UK with the rest from foreign markets.

However, those UK sales delivered around 86% of profit before tax, much of it from the firm’s largest customer, the NHS. That outcome suggests selling products to places like Australia, Germany and the rest of the world may involve bigger costs. It’s also possible profit margins are lower.

So one risk here is the company’s focus on international expansion may not prove to be as lucrative as hoped. For example, the US market is a well-known graveyard for the hopes and dreams of many previous UK companies. Tesco is one that tried and failed to conquer the market.

Tristel said today it has encountered “more purchasing bureaucracy” in the US than anticipated. So it’s taking longer than expected for some customers to adopt the products. However, “momentum is growing” across the pond, and the American healthcare market is the world’s largest.

I think the setbacks and uncertainty reflect in the share price chart.

However, the weakness has sharpened up the valuation somewhat. With the stock near 388p, the forward-looking price-to-earnings (P/E) rating for the current trading year is just below 25. That’s still a growth rating, but not wildly excessive.

The US market is just one international region in which the company is making progress. So, on balance and despite the risks, I’d conduct deeper research now with a view to possibly picking up a few of the shares to hold long term.

The post Why this AIM stock is one to consider buying now appeared first on The Motley Fool UK.

This company has a market cap of just £202m. Here’s why I’m interested.

Infection prevention

Tristel is a medical disinfectant specialist whose products can be found in hospitals, clinics and other healthcare settings.

The firm has two main product lines. It makes surface disinfectant products and manual disinfectant wipes and solutions for medical devices.

Both use its proprietary chlorine dioxide (ClO₂) chemistry. It says: “We are unique worldwide in using ClO₂ as a high-performance disinfectant.”

ClO₂ is effective against a wide range of pathogens, including bacteria, viruses, and fungi. This makes it a versatile disinfectant solution.

Strong growth

Revenue has grown from £22.2m in 2018 to £36m in 2023. For fiscal 2024 (which ends in June), the firm is forecast to post £41m in revenue.

Looking ahead, analysts see it doubling its top line over the next five years. So there are strong growth expectations here, which I like.

What’s more, the company is expected to report a net profit of £6.7m for this financial year, a 32% year-on-year rise. And profits are tipped to grow steadily in future too.

The firm’s operating margin is a healthy 15%, while it had a cash position of £10.8m at the end of 2023.

There’s even a dividend yielding 3.1%, though cover looks thin at just 1.1 times earnings. That is, the earnings per share only just covers the dividend per share.

Share price performance

Reflecting its progress, the stock is up a whopping 483% over the past 10 years. However, it’s down 37% since reaching a peak in 2021.

It took a dive back then as the pandemic delayed many operations, reducing the need for medical device disinfectants (which make up the bulk of Tristel’s sales).

Since then, higher interest rates have put pressure on small-cap stocks. So the shares are yet to fully recover, despite the actual business continuing to grow.

Big growth potential

While the NHS is Tristel’s largest customer, it also sells its products directly into 14 other countries.

Of these, the vast US healthcare market holds the greatest promise. Ultrasound is the firm’s biggest segment globally, and in 2023 it launched Tristel ULT — a disinfection product used on ultrasound units — in the US.

This has also been cleared by regulators in Canada, while other products are being submitted to US regulators. 

What I like here is that Tristel is already a global leader in manual high-level disinfection of medical devices. There are 50m ultrasound scans in North America requiring high-level disinfection annually, but not all probes fit into the cleaning machines.

The firm sees this translating into a $100m per year revenue opportunity for itself and its US manufacturing partner.

Watchlist stock

The only bugbear I have here is valuation. The stock is trading at 30 times forecast earnings. There could be risk investing at this level if US sales don’t grow as strongly as anticipated.

Still, if the market is right about the firm doubling revenue in the next five years, the stock could surge much higher. It’s near the top of my watchlist.

The post 1 small-cap stock with a 3.1% yield to consider for a Stocks and Shares ISA appeared first on The Motley Fool UK.